Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093197
Status:
COMPLETED
Last Update Posted:
2011-09-02
First Post:
2004-10-04
Brief Title:
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Sponsor:
KAI Pharmaceuticals
Organization:
KAI Pharmaceuticals
Study Overview
Official Title:
Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack However up to 25-50 of patients who have angioplasty may have ongoing damage to the heart muscle when the blockage is opened and blood flow is restored Complications which may result from this ongoing damage include a larger area of damaged muscle in the heart enlargement of the heart an increased risk of death and an increased risk of heart failure Some of the ongoing damage may involve increased levels of the protein kinase C PKC enzyme KAI-9803 is a selective inhibitor of delta PKC In this study delta PKC is used with angioplasty and other standard procedures to restore blood flow after a heart attack This study is designed to evaluate safety of different amounts of KAI-9803 when used in treating heart attack patients undergoing angioplasty We will also try to evaluate whether KAI-9803 can reduce the amount of heart muscle damage and the complications that may occur in these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None